524718 | Phosphodiesterase Inhibitor Set I - Calbiochem

524718
Price could not be retrieved
Minimum Quantity needs to be mulitiple of
Upon Order Completion More Information
You Saved ()
 
Request Pricing
Limited AvailabilityLimited Availability
Stocked 
Discontinued
Limited Quantities Available
Available
    Remaining : Will advise
      Remaining : Will advise
      Will advise
      Contact Customer Service
      View Pricing & Availability
      Click To Print This Page

      Overview

      Replacement Information

      Key Specifications Table

      Pricing & Availability

      Catalog NumberAvailability Packaging Qty/Pack Price Quantity
      524718-1SET
      Retrieving availability...
      Limited AvailabilityLimited Availability
      Stocked 
      Discontinued
      Limited Quantities Available
      Available
        Remaining : Will advise
          Remaining : Will advise
          Will advise
          Contact Customer Service

          Glass bottle 1 set
          Retrieving price...
          Price could not be retrieved
          Minimum Quantity needs to be mulitiple of
          Upon Order Completion More Information
          You Saved ()
           
          Request Pricing
          Description
          OverviewA convenient set of inhibitors that are selective for PDE types I, III, IV, and V. Contains 10 mg of 8-Methoxymethyl-3-isobutyl-1-methylxanthine (Cat. No. 454202), a Ca2+/CaM-dependent PDE (PDE I) inhibitor; 1 mg of 4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline (Cat. No. 475250), a cGMP-specific PDE (PDE V) inhibitor; 5 mg of Rolipram (Cat. No. 557330), a cAMP-specific PDE (PDE IV) inhibitor; and 10 mg of Trequinsin, Hydrochloride (Cat. No. 382425), a cGMP-inhibited PDE (PDE III) inhibitor. Supplied with data sheet.
          Catalogue Number524718
          Brand Family Calbiochem®
          SynonymsPDE Inhibitor Set
          Application Data
          References
          ReferencesTakase, Y., et al. 1994. J. Med. Chem. 37, 2106.
          Underwood, D.C., et al. 1994. J. Pharmacol. Exp. Ther. 270, 250.
          Wells, J.N. and Miller, J.R. 1988. Methods Enzymol. 159, 489.
          Ruppert, D. and Weithmann, K.U. 1982. Life Sciences 31, 2037.
          Product Information
          FormSolid
          Applications
          Biological Information
          Primary TargetPDE I, PDE III, PDE IV, PDE V
          Physicochemical Information
          Dimensions
          Materials Information
          Toxicological Information
          Safety Information according to GHS
          Safety Information
          R PhraseR: 36/37/38

          Irritating to eyes, respiratory system and skin.
          S PhraseS: 26-36

          In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.
          Wear suitable protective clothing.
          Product Usage Statements
          Storage and Shipping Information
          Ship Code Ambient Temperature Only
          Toxicity Multiple Toxicity Values, refer to MSDS
          Storage +2°C to +8°C
          Do not freeze Ok to freeze
          Special InstructionsFollowing reconstitution of each inhibitor, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
          Packaging Information
          Transport Information
          Supplemental Information
          Specifications

          Documentation

          SDS

          Title

          Safety Data Sheet (SDS) 

          Certificates of Analysis

          TitleLot Number
          524718

          References

          Reference overview
          Takase, Y., et al. 1994. J. Med. Chem. 37, 2106.
          Underwood, D.C., et al. 1994. J. Pharmacol. Exp. Ther. 270, 250.
          Wells, J.N. and Miller, J.R. 1988. Methods Enzymol. 159, 489.
          Ruppert, D. and Weithmann, K.U. 1982. Life Sciences 31, 2037.
          Data Sheet

          Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

          Revision17-September-2009 RFH
          SynonymsPDE Inhibitor Set
          Application Data
          DescriptionPhosphodiesterases (PDEs) play an important role in the regulation of cAMP and cGMP levels in the cell. At least five PDE isozymes have been characterized that are differentially expressed and regulated in different cell types: Ca2+-calmodulin-dependent (PDE I); cGMP-stimulated (PDE II); cGMP-inhibited (PDE III); cAMP-specific (PDE IV); cGMP-specific (PDE V). These isozymes exhibit significant homology in their catalytic domain. The cyclic nucleotides are important regulators of many different cellular processes. They are involved in inflammation, asthma, and cardiovascular complications. Hence, specific inhibitors of the PDE isozymes have a potential for use as therapeutic agents. The Phosphodiesterase Inhibitor Set I contains the following inhibitors that are selective for PDE types l, III, IV, and V:

          • 8-Methoxymethyl-3-isobutyl-1-methylxanthine(8-Methoxymethyl-IBMX) (Cat. No. 454202), 10 mg
          • 4-{[3',4'-(Methylenedioxy) benzyl]amino}-6-methoxyquinazoline (Cat. No. 475250), 1 mg
          • Rolipram (Cat. No. 557330), 5 mg
          • Trequinsin, Hydrochloride (Cat. No. 382425), 10 mg
          FormSolid
          SolubilitySee properties table for specific solvent and recommended stock concentration.
          Storage +2°C to +8°C
          Do Not Freeze Ok to freeze
          Special InstructionsFollowing reconstitution of each inhibitor, aliquot and freeze (-20°C). Stock solutions are stable for up to 1 month at -20°C.
          Toxicity Multiple Toxicity Values, refer to MSDS
          ReferencesTakase, Y., et al. 1994. J. Med. Chem. 37, 2106.
          Underwood, D.C., et al. 1994. J. Pharmacol. Exp. Ther. 270, 250.
          Wells, J.N. and Miller, J.R. 1988. Methods Enzymol. 159, 489.
          Ruppert, D. and Weithmann, K.U. 1982. Life Sciences 31, 2037.